A Newspaper for the health conscious

We are hiring

US FDA's final nod to Cipla's Lipid Regulating Tablets

1 1 1 1 1 1 1 1 1 1 Rating 5.00 (2 Votes)

DTMT Network

  The US Food and Drug Administration (FDA) has given its final nod to Cipla, an Indian drug company, for lipid regulating Fenofibrate tablets.

Cipla, in a filing to the BSE, has said that the company has received final approval for its abbreviated new drug application (ANDA) for Fenofibrate tablets USP 48mg and 145mg, from the United States Food and Drug Administration.

The company said that the tablets are generic versions of AbbVie’s tablets. Citing the data from IMS Health, the company said that Tricor tablets and generic equivalents had US sales of approximately $307 million for the 12-month period ending October, 2016.

Leave your comments



  • No comments found


  • No comments found